IN2015MN00139A - - Google Patents
Download PDFInfo
- Publication number
- IN2015MN00139A IN2015MN00139A IN139MUN2015A IN2015MN00139A IN 2015MN00139 A IN2015MN00139 A IN 2015MN00139A IN 139MUN2015 A IN139MUN2015 A IN 139MUN2015A IN 2015MN00139 A IN2015MN00139 A IN 2015MN00139A
- Authority
- IN
- India
- Prior art keywords
- protein
- fragments
- present
- hetero dimeric
- immunoglobulinvariants
- Prior art date
Links
- 101710120037 Toxin CcdB Proteins 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 229940072221 immunoglobulins Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261705278P | 2012-09-25 | 2012-09-25 | |
| PCT/EP2013/069989 WO2014049003A1 (en) | 2012-09-25 | 2013-09-25 | Purification of hetero-dimeric immunoglobulins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015MN00139A true IN2015MN00139A (Direct) | 2015-10-16 |
Family
ID=49237223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN139MUN2015 IN2015MN00139A (Direct) | 2012-09-25 | 2013-09-25 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20150239991A1 (Direct) |
| EP (2) | EP3401337A1 (Direct) |
| JP (5) | JP2015529236A (Direct) |
| KR (1) | KR20150076172A (Direct) |
| CN (1) | CN104968685A (Direct) |
| AU (2) | AU2013322710A1 (Direct) |
| CA (2) | CA2886036A1 (Direct) |
| HK (1) | HK1215950A1 (Direct) |
| IL (2) | IL237872B (Direct) |
| IN (1) | IN2015MN00139A (Direct) |
| WO (1) | WO2014049003A1 (Direct) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| JP5616428B2 (ja) | 2009-04-07 | 2014-10-29 | ロシュ グリクアート アクチェンゲゼルシャフト | 三価の二重特異性抗体 |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| CA2781519A1 (en) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| EP2609111B1 (en) | 2010-08-24 | 2017-11-01 | F. Hoffmann-La Roche AG | Bispecific antibodies comprising a disulfide stabilized-fv fragment |
| WO2012116927A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Monovalent antigen binding proteins |
| MX341921B (es) | 2011-02-28 | 2016-09-07 | Hoffmann La Roche | Proteinas de union a antigeno. |
| CA2886036A1 (en) * | 2012-09-25 | 2014-04-03 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| HK1213578A1 (zh) | 2013-04-29 | 2016-07-08 | 豪夫迈‧罗氏有限公司 | 结合人fcrn的修饰的抗体和使用方法 |
| CA2922979A1 (en) * | 2013-09-03 | 2015-03-12 | Novimmune S.A. | Readily isolated bispecific binding molecules with native format having mutated constant regions |
| KR20160044060A (ko) | 2013-10-11 | 2016-04-22 | 에프. 호프만-라 로슈 아게 | 다중특이적 도메인 교환된 통상의 가변 경쇄 항체 |
| KR20160090308A (ko) * | 2013-11-04 | 2016-07-29 | 그렌마크 파머수티칼스 에스. 아. | T 세포 재표적 이형-이량체 면역글로불린의 생산 |
| CN105916880B (zh) | 2014-01-15 | 2020-01-17 | 豪夫迈·罗氏有限公司 | 具有改善的蛋白A结合作用的Fc区变体 |
| LT3122781T (lt) | 2014-03-28 | 2020-03-25 | Xencor, Inc. | Bispecifiniai antikūnai, kurie jungiasi prie cd38 ir cd3 |
| AR101262A1 (es) * | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
| JP6744292B2 (ja) * | 2014-07-29 | 2020-08-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 多重特異性抗体 |
| MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| IL252467B (en) | 2014-11-26 | 2022-06-01 | Xencor Inc | Heterodimeric antibodies that bind cd3 and cd38 |
| JP6721590B2 (ja) | 2014-12-03 | 2020-07-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 多重特異性抗体 |
| WO2017005649A1 (en) | 2015-07-09 | 2017-01-12 | Genmab A/S | Bispecific and multispecific antibodies and method for isolation of such |
| EP3365366B1 (en) | 2015-10-25 | 2021-07-14 | Sanofi | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection |
| GB201602156D0 (en) * | 2016-02-05 | 2016-03-23 | Jones Philip C And Boku University Of Natural Resources And Life Sciences | Heterodimers and purification thereof |
| MY192090A (en) | 2016-04-13 | 2022-07-26 | Sanofi Sa | Trispecific and/or trivalent binding proteins |
| JP7195929B2 (ja) * | 2016-04-13 | 2022-12-26 | サノフイ | 三重特異性および／または三価結合タンパク質 |
| AU2017259869A1 (en) * | 2016-05-02 | 2018-09-27 | F. Hoffmann-La Roche Ag | The contorsbody - a single chain target binder |
| CN109790215B (zh) * | 2016-09-29 | 2023-06-30 | 北京韩美药品有限公司 | 异源二聚体免疫球蛋白构建体和其制备方法 |
| PE20191080A1 (es) | 2016-11-18 | 2019-08-20 | Beijing Hanmi Pharmaceutical Co Ltd | Anticuerpo biespecifico heterodimerico estructural de anticuerpo natural anti-pd-1/anti-her2 y metodo para preparar el mismo |
| TW202515920A (zh) | 2017-04-11 | 2025-04-16 | 美商因荷布瑞克斯生物科學公司 | 具有經受限cd3結合的多重特異性多肽構築體及使用其之方法 |
| WO2019153200A1 (zh) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| CN111902720B (zh) | 2018-03-21 | 2025-02-07 | 沃特世科技公司 | 基于非抗体高亲和力的样品制备、吸附剂、装置和方法 |
| CA3096123A1 (en) | 2018-04-11 | 2019-10-17 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses |
| FR3080621B1 (fr) * | 2018-04-26 | 2022-12-09 | Univ Limoges | Nouvelle classe d'immunoglobuline recombinante de type g : igg5, codee par le pseudo-gene gamma humain de chaine lourde |
| CN112513074A (zh) * | 2018-06-22 | 2021-03-16 | 健玛保 | 生产两种或更多种不同抗体的受控混合物的方法 |
| CA3105891A1 (en) | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| EP3864045A2 (en) | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
| CN113518647A (zh) | 2018-10-11 | 2021-10-19 | 印希比股份有限公司 | 5t4单域抗体及其治疗性组合物 |
| JP2022512684A (ja) | 2018-10-11 | 2022-02-07 | インヒブルクス インコーポレイテッド | Ｂ７ｈ３シングルドメイン抗体およびその治療用組成物 |
| EP3864049A1 (en) | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
| CA3124770A1 (en) | 2018-12-24 | 2020-07-02 | Sanofi | Pseudofab-based multispecific binding proteins |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| MX2022006972A (es) * | 2019-12-26 | 2022-08-04 | Abl Bio Inc | Metodo para la purificacion de peptido biologicamente activo utilizando cromatografia de afinidad con proteina a. |
| EP4097129A1 (en) | 2020-01-29 | 2022-12-07 | Inhibrx, Inc. | Cd28 single domain antibodies and multivalent and multispecific constructs thereof |
| AU2021358659A1 (en) | 2020-10-07 | 2023-06-08 | Dren Bio Management, Inc. | Anti-dectin-1 antibodies and methods of use thereof |
| WO2022266223A1 (en) | 2021-06-16 | 2022-12-22 | Alector Llc | Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof |
| EP4355783A1 (en) | 2021-06-16 | 2024-04-24 | Alector LLC | Monovalent anti-mertk antibodies and methods of use thereof |
| JP2023092810A (ja) * | 2021-12-22 | 2023-07-04 | 国立大学法人東京農工大学 | 変異抗体、変異抗体の製造方法 |
| WO2023240109A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules for modulating t-cell activity, and uses thereof |
| JP2025528752A (ja) | 2022-07-29 | 2025-09-02 | アレクトル エルエルシー | トランスフェリン受容体抗原結合ドメイン及びその使用法 |
| WO2024026471A1 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
| WO2024050493A2 (en) * | 2022-09-02 | 2024-03-07 | Zoetis Services Llc | Equine antibody mutants |
| WO2024102948A1 (en) | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
| US12195546B2 (en) | 2022-12-19 | 2025-01-14 | Sanofi | CD28/OX40 bispecific antibodies |
| WO2025038668A1 (en) | 2023-08-14 | 2025-02-20 | Voro Therapeutics, Inc. | Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof |
| WO2025087386A1 (zh) * | 2023-10-25 | 2025-05-01 | 正大天晴药业集团南京顺欣制药有限公司 | 抗her2抗体药物偶联物治疗乳腺癌的用途 |
| WO2025166040A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof |
| WO2025166077A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Compositions comprising progranulin and uses thereof |
| WO2025166045A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF |
| WO2025166042A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
| WO2025240670A2 (en) | 2024-05-15 | 2025-11-20 | Abalytics Oncology, Inc. | Anti-pd-1 antibodies and related binding molecules and methods and uses thereof |
| WO2025264572A1 (en) | 2024-06-17 | 2025-12-26 | Alector Llc | Transferrin receptor antigen-binding domains and uses therefor |
| WO2026013158A1 (en) | 2024-07-10 | 2026-01-15 | Cytospire Therapeutics Limited | Antibodies binding to constant domains of gamma delta t-cell receptors |
| WO2026013159A1 (en) | 2024-07-10 | 2026-01-15 | Cytospire Therapeutics Limited | Antibodies binding to constant domains of gamma delta t-cell receptors |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| ATE204902T1 (de) | 1990-06-29 | 2001-09-15 | Large Scale Biology Corp | Melaninproduktion durch transformierte mikroorganismen |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE122009000068I2 (de) | 1994-06-03 | 2011-06-16 | Ascenion Gmbh | Verfahren zur Herstellung von heterologen bispezifischen Antikörpern |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| DK0826696T3 (da) | 1996-09-03 | 2002-09-23 | Gsf Forschungszentrum Umwelt | Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet |
| US8142780B2 (en) * | 1998-08-20 | 2012-03-27 | Strox Biopharmaceuticals, Llc | Anti-bacterial antibodies |
| US6322788B1 (en) * | 1998-08-20 | 2001-11-27 | Stanley Arthur Kim | Anti-bacterial antibodies and methods of use |
| NZ565044A (en) * | 2005-06-17 | 2010-05-28 | Elan Pharma Int Ltd | Methods of purifying anti A beta antibodies with calcium chloride |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| US20090182127A1 (en) | 2006-06-22 | 2009-07-16 | Novo Nordisk A/S | Production of Bispecific Antibodies |
| DK2716301T3 (en) | 2007-02-16 | 2017-07-31 | Merrimack Pharmaceuticals Inc | ANTIBODIES AGAINST ERBB3 AND APPLICATIONS THEREOF |
| SI2235064T1 (sl) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov |
| CA2738565C (en) * | 2008-10-01 | 2023-10-10 | Micromet Ag | Cross-species-specific psmaxcd3 bispecific single chain antibody |
| US20120009182A1 (en) * | 2008-12-23 | 2012-01-12 | Genentech, Inc. | Immunoglobulin variants with altered binding to protein a |
| KR20110122859A (ko) | 2009-02-23 | 2011-11-11 | 그렌마크 파머수티칼스 에스. 아. | Ｃｄ１９에 결합하는 인간화된 항체 및 그것의 용도 |
| ES2572728T3 (es) | 2009-03-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Anticuerpos anti-HER biespecíficos |
| CA2766220C (en) * | 2009-06-26 | 2021-02-09 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
| HRP20200464T1 (hr) * | 2009-12-25 | 2020-06-26 | Chugai Seiyaku Kabushiki Kaisha | Metoda modifikacije polipeptida za pročišćavanje polipeptidnih multimera |
| ES2989108T3 (es) * | 2010-04-20 | 2024-11-25 | Genmab As | Proteínas que contienen FC de anticuerpos heterodiméricos y métodos para producir las mismas |
| EP2688909A2 (en) | 2011-03-25 | 2014-01-29 | Glenmark Pharmaceuticals S.A. | Hetero-dimeric immunoglobulins |
| US9114516B2 (en) | 2011-07-21 | 2015-08-25 | Illinois Tool Works Inc. | Portable combustion gas-powered tools with combustion chamber lockout system |
| SG10201805291TA (en) * | 2011-10-27 | 2018-08-30 | Genmab As | Production of heterodimeric proteins |
| WO2013131555A1 (en) | 2012-03-06 | 2013-09-12 | Foss Analytical Ab | Method, software and graphical user interface for forming a prediction model for chemometric analysis |
| CA2867020C (en) | 2012-03-13 | 2022-11-15 | Novimmune S.A. | Readily isolated bispecific antibodies with native immunoglobulin format |
| CA2886036A1 (en) * | 2012-09-25 | 2014-04-03 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| KR20160090308A (ko) * | 2013-11-04 | 2016-07-29 | 그렌마크 파머수티칼스 에스. 아. | T 세포 재표적 이형-이량체 면역글로불린의 생산 |
-
2013
- 2013-09-25 CA CA2886036A patent/CA2886036A1/en not_active Abandoned
- 2013-09-25 CA CA3061557A patent/CA3061557A1/en active Pending
- 2013-09-25 AU AU2013322710A patent/AU2013322710A1/en not_active Abandoned
- 2013-09-25 WO PCT/EP2013/069989 patent/WO2014049003A1/en not_active Ceased
- 2013-09-25 KR KR1020157010732A patent/KR20150076172A/ko not_active Ceased
- 2013-09-25 HK HK16103843.5A patent/HK1215950A1/zh unknown
- 2013-09-25 EP EP18177798.8A patent/EP3401337A1/en not_active Withdrawn
- 2013-09-25 IN IN139MUN2015 patent/IN2015MN00139A/en unknown
- 2013-09-25 JP JP2015532465A patent/JP2015529236A/ja active Pending
- 2013-09-25 EP EP13766540.2A patent/EP2900696A1/en not_active Ceased
- 2013-09-25 CN CN201380061419.1A patent/CN104968685A/zh active Pending
- 2013-09-25 US US14/431,207 patent/US20150239991A1/en not_active Abandoned
-
2015
- 2015-03-22 IL IL237872A patent/IL237872B/en active IP Right Grant
-
2018
- 2018-02-07 JP JP2018020450A patent/JP2018104444A/ja active Pending
- 2018-06-15 AU AU2018204314A patent/AU2018204314B2/en active Active
- 2018-11-30 JP JP2018224809A patent/JP6856610B2/ja not_active Expired - Fee Related
-
2019
- 2019-02-14 US US16/275,821 patent/US20200010568A1/en not_active Abandoned
- 2019-09-09 IL IL269207A patent/IL269207B/en unknown
-
2020
- 2020-03-04 JP JP2020036853A patent/JP2020105203A/ja not_active Ceased
-
2022
- 2022-06-07 JP JP2022092045A patent/JP2022116326A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014049003A1 (en) | 2014-04-03 |
| JP2018104444A (ja) | 2018-07-05 |
| JP2015529236A (ja) | 2015-10-05 |
| CN104968685A (zh) | 2015-10-07 |
| JP2020105203A (ja) | 2020-07-09 |
| CA2886036A1 (en) | 2014-04-03 |
| IL237872A0 (en) | 2015-05-31 |
| IL237872B (en) | 2019-09-26 |
| AU2018204314A1 (en) | 2018-07-05 |
| AU2013322710A1 (en) | 2015-04-16 |
| CA3061557A1 (en) | 2014-04-03 |
| AU2018204314B2 (en) | 2020-05-14 |
| EP3401337A1 (en) | 2018-11-14 |
| IL269207A (en) | 2019-11-28 |
| US20200010568A1 (en) | 2020-01-09 |
| JP2019073512A (ja) | 2019-05-16 |
| JP6856610B2 (ja) | 2021-04-07 |
| AU2013322710A2 (en) | 2015-05-07 |
| IL269207B (en) | 2022-02-01 |
| JP2022116326A (ja) | 2022-08-09 |
| US20150239991A1 (en) | 2015-08-27 |
| EP2900696A1 (en) | 2015-08-05 |
| HK1215950A1 (zh) | 2016-09-30 |
| KR20150076172A (ko) | 2015-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015MN00139A (Direct) | ||
| IL282226A (en) | ST2 antigen-binding proteins | |
| WO2013138793A3 (en) | Affinity reagants for protein purification | |
| PH12014501108A1 (en) | Anti-il-36r antibodies | |
| PH12014502406A1 (en) | Anti-il-23p19 antibodies | |
| IL254652B (en) | Unnatural albumin binding sites | |
| EA201791693A1 (ru) | Гетеродимерные иммуноглобулины | |
| PH12013500810B1 (en) | Anti-il-23 antibodies | |
| TN2015000124A1 (en) | Compositions and methods for antibodies targeting epo | |
| GB201012599D0 (en) | Process for purifying proteins | |
| EP3067367A4 (en) | Method for purifying recombinant protein | |
| IL229722A0 (en) | Dimeric binding proteins based on modified ubiquitin | |
| SG2014010334A (en) | Fn14 binding proteins and uses thereof | |
| PH12015500752A1 (en) | Her3 antigen binding proteins binding to the beta-hairpin of her3 | |
| MX2014001766A (es) | Anticuerpos de neuregulina y sus usos. | |
| WO2013093627A3 (en) | In silico affinity maturation | |
| MX2015004892A (es) | Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21. | |
| WO2013160291A3 (en) | Archease as rna ligase complex member | |
| TN2014000207A1 (en) | Anti il-36r antibodies | |
| TN2013000186A1 (en) | Anti-il-23 antibodies |